Adolescent Medicine · Supplementary · from Adolescent Medicine

Case 3: Adolescent Contraception Counseling

Patient Presentation

Demographics: 16-year-old female high school student

Chief Complaint: "I want to go on birth control. I don't want my parents to know."

History of Present Illness: The patient presents alone to the adolescent medicine clinic requesting contraception. She reports that she has been in a relationship with her 17-year-old boyfriend for the past 6 months and they have been sexually active for the past 2 months. They have been using condoms inconsistently — she estimates condom use approximately 50% of the time. She reports one episode of unprotected intercourse 4 days ago and is concerned about pregnancy, though her last menstrual period was 10 days ago (Day 14 of her cycle).

She has done her own research online and is interested in "the implant" (etonogestrel subdermal implant) because a friend told her it lasts for years and she "won't have to remember to take a pill every day." She explicitly requests confidentiality and does not want her parents informed. She states that she fears her parents, who are "very conservative and religious," would "disown" her if they learned she was sexually active. She denies any pressure to have sex, abuse, or coercion by her partner. She reports the relationship is "healthy and equal."

She has not previously used any form of hormonal contraception. She reports no history of sexually transmitted infections (STIs). She has never been pregnant. She has no other medical concerns at this visit.

Past Medical History:

• Migraine with aura (2-3 episodes per year since age 13; visual aura with scintillating scotoma preceding unilateral headache)
• Mild intermittent asthma (well controlled, uses albuterol PRN rarely)
• No surgical history
• No known drug allergies
• Menarche at age 12; regular cycles, 28-30 day intervals, 4-5 day duration, moderate flow, mild dysmenorrhea managed with ibuprofen

Medications:

• Albuterol MDI as needed (used <1x per month)
• Ibuprofen as needed for menstrual cramps and migraines
• No hormonal medications

Social History:

• 11th grade student, GPA 3.5
• Part-time job at a retail store (weekends)
• Lives with both biological parents and a 13-year-old sister
• One sexual partner (current boyfriend, age 17); vaginal intercourse only; no anal or oral intercourse
• Condom use approximately 50% of the time
• Denies tobacco, alcohol, or drug use
• No history of sexual abuse, coercion, or dating violence (screened with validated tool)
• Appears emotionally mature and well-informed for her age
• HEADSS assessment: no red flags identified beyond the current contraceptive need

Family History:

• Mother: hypertension, history of blood clots in the leg after surgery (provoked DVT at age 42)
• Father: type 2 diabetes
• Maternal grandmother: stroke at age 68
• No known thrombophilias tested in the family

Physical Examination

• Vital Signs: BP 112/72 mmHg, HR 74 bpm, RR 16/min, Temp 36.6°C, Weight 62 kg, Height 163 cm, BMI 23.3 kg/m²
• General: Well-appearing, well-nourished adolescent female; Tanner stage V; appears comfortable; no acute distress
• Cardiovascular: Regular rate and rhythm; no murmurs
• Abdomen: Soft, non-tender, non-distended; no masses
• Skin: No acne; no hirsutism; no skin changes suggestive of hormonal abnormalities
• No pelvic examination performed (not required for contraception initiation per ACOG guidelines)
• Extremities: No edema, no varicosities, no signs of deep vein thrombosis

Workup and Results

Laboratory Studies:

Imaging/Additional Studies:

• None required for contraception counseling and initiation
• Pelvic examination not indicated (ACOG and AAP guidelines state that pelvic examination is not required prior to initiating contraception, including IUDs and implants in adolescents)

Clinical Image

Educational chart comparing long-acting reversible contraceptive (LARC) methods and other contraceptive options for adolescents, including effectiveness rates, duration, advantages, and contraindications. Source: Educational illustration.

Diagnosis

Reproductive Health Visit: Contraception Counseling in an Adolescent with Migraine with Aura

Key Diagnostic Criteria:

• Sexually active adolescent requesting contraception — appropriate and timely clinical encounter
• Migraine with aura — absolute contraindication (USMEC Category 4) to combined hormonal contraceptives (combined oral contraceptives, patch, ring) due to elevated risk of ischemic stroke
• Family history of provoked DVT (mother) — low risk but warrants consideration; thrombophilia testing not routinely indicated for provoked DVT in a family member
• Confidentiality request — all 50 US states and DC allow minors to consent to contraceptive services without parental consent; specific laws vary by state
• Recent unprotected intercourse 4 days ago at Day 14 of cycle — emergency contraception should be discussed, though within the fertile window, pregnancy test is negative

Treatment Plan

1. Contraceptive counseling using a tiered approach (ACOG/AAP recommended):

• Tier 1 — Most effective (LARC methods): Etonogestrel implant (Nexplanon) and intrauterine devices (hormonal: Mirena/Kyleena/Liletta; copper: Paragard). Failure rate <1%. Recommended as first-line for adolescents by ACOG and AAP.
• Tier 2 — Effective: Injectable (DMPA), combined hormonal methods. Note: Combined hormonal contraceptives (pill, patch, ring) are CONTRAINDICATED in this patient due to migraine with aura (USMEC Category 4 — unacceptable health risk due to 2-4x increased risk of ischemic stroke).
• Tier 3 — Moderately effective: Progestin-only pills, condoms, other barrier methods.
• Patient's preference for the etonogestrel implant is an excellent choice given her history of migraine with aura — progestin-only methods are USMEC Category 1 (no restriction) for migraine with aura.

1. Etonogestrel subdermal implant (Nexplanon) insertion:

• Timing: Can be inserted today (Quick Start method) — she is on Day 14 of her cycle, pregnancy test negative, last unprotected intercourse 4 days ago. Use backup method (condoms) for 7 days after insertion.
• Procedure: Implant placed subdermally in the medial aspect of the non-dominant upper arm, 8-10 cm above the medial epicondyle, in the sulcus between biceps and triceps. Local anesthesia with 1% lidocaine. Palpate implant after insertion.
• Duration: Effective for up to 3 years (FDA-approved; evidence supports efficacy for up to 5 years)
• Side effects counseled: Irregular bleeding (most common, especially in first 6 months), amenorrhea (in approximately 22%), headache, mood changes, weight change (average 2-3 lbs over 3 years, not clinically significant)
• Efficacy: >99.9% — the most effective reversible contraceptive available

1. Emergency contraception discussion:

• Unprotected intercourse 4 days ago at Day 14 (likely near ovulation): Ulipristal acetate (Ella) 30 mg single dose is the most effective oral emergency contraception up to 5 days post-intercourse and is effective closer to ovulation than levonorgestrel
• Alternatively, copper IUD (Paragard) is the most effective emergency contraception (>99%) and can be placed up to 5 days after unprotected intercourse
• If she chooses ulipristal acetate today and the implant, the implant should be placed starting 5 days after ulipristal (as progestins may decrease ulipristal efficacy); alternatively, if she accepts the small residual pregnancy risk, the implant can be placed today

1. STI screening and prevention:

• Chlamydia and gonorrhea screening (NAAT, urine): obtained today — recommended annually for all sexually active females <25 years
• HIV and syphilis screening: obtained today
• Hepatitis B immunity: verify immunization records
• HPV vaccination: verify status (Gardasil 9; if not completed, administer catch-up series)
• Counsel on dual protection: LARC prevents pregnancy but NOT STIs; emphasize consistent condom use for STI prevention
• Provide condoms at the visit

1. Confidentiality and legal considerations:

• Document the patient's capacity to provide informed consent (mature minor doctrine; state-specific minor consent laws for reproductive health apply)
• Ensure confidential billing: discuss implications for explanation of benefits (EOB) if on parents' insurance; explore Title X family planning clinic or state-funded program if insurance confidentiality cannot be guaranteed
• Document HEADSS assessment and screening for coercion, trafficking, and abuse (negative in this case)
• Address the age-of-consent question: both partners are 16 and 17 (within the Romeo-and-Juliet exemption range in most jurisdictions; no mandatory reporting obligation in most states for consensual sexual activity between peers of similar age)

1. Follow-up:

• Return in 3 months to review implant tolerability, bleeding pattern, and STI results
• Annual STI screening
• Repeat pregnancy test if amenorrheic and concerned, or if symptoms develop
• Open invitation to return for any concerns without an appointment requirement (adolescent-friendly access)

Key Learning Points

• Migraine with aura is an absolute contraindication (USMEC Category 4) to all estrogen-containing contraceptives (combined oral contraceptive pills, combined patch, combined vaginal ring) due to a 2-4x increased risk of ischemic stroke; progestin-only methods (implant, hormonal IUD, POP, DMPA) are safe (Category 1-2).
• LARC methods (implants and IUDs) are recommended as first-line contraception for adolescents by ACOG, AAP, and WHO because they eliminate adherence barriers and have the lowest failure rates (<1%); myths about IUD use in nulliparous adolescents are unfounded.
• A pelvic examination is NOT required prior to initiating any form of contraception, including IUDs and implants; this is a common misconception that creates barriers to adolescent contraceptive access.
• Confidentiality is the cornerstone of adolescent reproductive healthcare; all US states allow minors to consent to contraceptive services, and providers should proactively address confidentiality concerns including insurance billing (EOB) and electronic health record access by parents.
• The Quick Start method (initiating contraception on the day of the visit regardless of cycle day) improves method uptake and reduces the risk of pregnancy between counseling and initiation; a negative pregnancy test and backup contraception for 7 days are sufficient.

All cases for this lecture as Markdown